Phosphatidylethanolamine synthesis in non-small cell lung cancer is significantly enhanced by ETNK2, whereas reduced ETNK2 expression in prostate cancer results from the loss of TET2 targeted demethylation (Kamdar et al., 2019; Lesko et al., 2021). The gene discussed is TET2; the disease is prostate cancer.